spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Olmesartan Medoxomil 

 HSMN NewsFeed - 26 Jul 2010
FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jun 2010
New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes
Biopharmaceuticals
 HSMN NewsFeed - 11 Feb 2010
FDA Approves Benicar(R) for the Treatment of High Blood Pressure in Children and Adolescents aged 6-16
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 13 May 2009
AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 May 2009
New Data Shows Blood Pressure Reduction Therapy With BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure
Biopharmaceuticals
 HSMN NewsFeed - 8 May 2009
New Data Shows AZOR(R) (Amlodipine and Olmesartan Medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Oct 2008
Mylan Receives Tentative FDA Approval for First-to-File Generic Version of Blood Pressure Drug Benicar HCT(R)
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 16 Jun 2008
New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
Biopharmaceuticals
 HSMN NewsFeed - 14 May 2008
New Data Shows 45 Percent of Patients With Stage 1 Hypertension Reached Normotension With BENICAR(R) and BENICAR HCT(R)
Biopharmaceuticals
 HSMN NewsFeed - 12 May 2008
Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
Biopharmaceuticals
 HSMN NewsFeed - 19 Mar 2008
Forest Laboratories Announces Resignation of Ivan Gergel, MD
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Feb 2008
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
Biopharmaceuticals
 HSMN NewsFeed - 22 Jan 2008
Novexel and Forest Laboratories Announce License Agreement for NXL 104, a Novel Broad-Spectrum Beta Lactamase Inhibitor
Biopharmaceuticals Licensing
 HSMN NewsFeed - 31 Dec 2007
Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Dec 2007
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 2 Dec 2007
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Nov 2007
Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
Biopharmaceuticals
 HSMN NewsFeed - 27 Sep 2007
AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Sep 2007
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Sep 2007
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 4 Sep 2007
Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 21 Aug 2007
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
Biopharmaceuticals
 HSMN NewsFeed - 31 May 2007
Topline Results of Phase III Study in Acute Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 May 2007
BENICAR HCT(R) Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 21 May 2007
Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 21 May 2007
Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 1 May 2007
Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 28 Mar 2007
Daiichi Sankyo, Inc. Announces Filing For WelChol Label Change to Include Ezetimibe Efficacy Data
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jan 2007
Forest Laboratories Announces Completion of Acquisition of Cerexa, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Jan 2007
Daiichi Sankyo, Inc. Announces Filing of Supplemental New Drug Application for WelChol in the Treatment of Type 2 Diabetes Mellitus
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 14 Dec 2006
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Dec 2006
Forest Laboratories Announces Acquisition of Cerexa, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 15 Nov 2006
New Study Confirms WelChol Improves Glycemic Control in Patients With Uncontrolled Type 2 Diabetes Mellitus on Insulin
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
Biopharmacetuicals Cardiology
 HSMN NewsFeed - 13 Nov 2006
WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
Biopharmaceuticals
 HSMN NewsFeed - 28 Oct 2006
Patient Recruitment to Resume Without Modification of Protocol for Desmoteplase Phase IIB/III Stroke Study DIAS-2
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Oct 2006
U.S. Food and Drug Administration Issues Non-Approvable Letter for Faropenem
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Sep 2006
Forest Laboratories Inc. Announces Appointment of Dr. Lawrence S. Olanoff as President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jul 2006
Forest Announces Federal Court Upholds Lexapro(R) Patent
Biopharmaceuticals Generics Litigation
Return to NewsFeed  

 Additional items found! 21

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 21 additional stories matching:
Olmesartan Medoxomil
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.